[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:skin-neurofibroma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":30,"states":31},"Skin Neurofibroma",3,2,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07102394","Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1",[12],"Phase 1","RECRUITING","2026-08-26T02:17:53.433613Z","2026-05-05T02:43:28.130062Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06159166","Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).",[20],"Phase 1\u002FPhase 2","2026-08-26T02:17:59.904383Z","2026-05-05T02:43:27.308579Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT06300502","Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:16:22.235886Z","2026-06-16T05:54:07.723494Z",[],[]]